69 results
8-K
EX-1.1
URGN
UroGen Pharma Ltd
18 Jun 24
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
5:07pm
herein, “Marketing Materials” means any materials or information provided to investors by, or with the approval of, the Company in connection … , toxic substances, hazardous substances, petroleum or petroleum products (collectively, “Hazardous Materials”) or to the manufacture, processing
424B5
URGN
UroGen Pharma Ltd
18 Jun 24
Prospectus supplement for primary offering
5:05pm
on May 2, 2022 and Definitive Additional Materials on Schedule A14A filed with the SEC on May 17, 2022;
our Quarterly Reports on Form 10-Q
424B5
URGN
UroGen Pharma Ltd
17 Jun 24
Prospectus supplement for primary offering
4:19pm
filed with the SEC on May 2, 2022 and Definitive Additional Materials on Schedule A14A filed with the SEC on May 17, 2022;
our Quarterly Reports
8-K
EX-99.1
amqsdoco
4 Mar 24
Regulation FD Disclosure
7:00am
8-K
EX-99.1
w0izhc dsvmj6xi
7 Feb 24
Regulation FD Disclosure
4:15pm
D
zvdd3 1ntryfpb
14 Aug 23
$120.00 mm in equity / options / securities to be acquired, sold $120.00 mm, 8 investors
2:06pm
DEFA14A
efi5c b7jlrnzr1
1 Aug 23
Additional proxy soliciting materials
4:23pm
8-K
EX-10.1
mvoyq38
27 Jul 23
UroGen Announces $120 Million Private Placement of Ordinary Shares
9:57am
424B5
q84 2yvwhkea6qr3rdh
1 Dec 22
Prospectus supplement for primary offering
4:05pm